Therefore, a study like ours is not able to separate the effect of weight loss and medication on cardiovascular events. Jayne Morgan, MD, a cardiologist and the Executive Director of Health and Community Education at the Piedmont Healthcare Corporation in Atlanta, GA, who was not involved in the meta-analysis, also noted that [the meta-analysis] does seem to address this with the random effects model which can be a powerful tool statistically, allowing the capture of the variability in weights across the studies. Certain effects of semaglutide are already known to affect heart health directly, said Saad, who further pointed out that the drug stabilizes atherosclerotic plaques, preventing the development of an acute myocardial infarction, and improves systemic inflammation caused by obesity. Semaglutides, said Morgan, act directly on blood vessels by improving blood flow to the heart and lowering blood pressure, on the kidneys by reducing the rate of GFR [glomerular filtration rate] decline, on the liver by reducing steatosis and improving cholesterol profile, and also on the central nervous system. If semaglutide provides direct cardiovascular benefits, does the meta-analysis imply the drug may have value for people at risk of cardiovascular disease who do not have diabetes, overweight, or obesity
Qualifying for insurance coverage of brand-name medications through type 2 diabetes or cardiovascular indications rather than weight loss alone can also dramatically reduce costs
By examining these alternatives, we aim to provide a comprehensive overview for those seeking different pathways to manage their weight and diabetes effectively
2.Gonzalez JS, Krause-Steinrauf H, Bebu I, Crespo-Ramos G, Hoogendoorn CJ, Naik AD, et al
More research is needed to fully understand why this happens
